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Abstract 1 
 2 
Purpose: To examine the acceptability, validity and reliability of EuroQoL 5-dimension 5-3 
level (EQ-5D-5L) and SF-6D health utility measures in patients with symptomatic benign 4 
thyroid nodules. 5 
 6 
Methods: Data from a randomized controlled trial (ClinicalTrials.gov Identifier: 7 
NCT02398721) of 294 patients with symptomatic thyroid nodules were utilized for this 8 
psychometric evaluation of HRQOL measurement. Three HRQOL questionnaires, generic 9 
12-item Short Form Health Survey (SF-12v2) and EQ-5D-5L, SF-6D, were interviewer-10 
administered at baseline and 2 weeks afterwards. Responses to SF-6D were transformed to 11 
SF-6D utility scores using Hong Kong population scoring algorithm derived by Standard 12 
Gamble whereas response to EQ-5D-5L were mapped onto EQ-5D-3L response via interim 13 
mapping algorithms and then converted to EQ-5D-5L utility scores using Chinese-specific 14 
value set. Construct validity was determined by evaluating Spearman correlation between SF-15 
12v2 scores and utility scores. Two-week test-retest reliability was assessed using intra-class 16 
correlation coefficient.  17 
 18 
Results: No significant (>15%) floor and ceiling effects were observed for SF-6D utility 19 
scores. The SF-6D utility scores had a moderate Spearman rank correlation with the SF-12v2 20 
domain score providing evidence for adequate construct validity. The SF-6D utility scores 21 
showed good test-retest reliability (0.794; range: 0.696-0.860). Better reliability was observed 22 
in SF-6D utility score than in EQ-5D-5L utility score. 23 
 24 
Conclusions: While the EQ-5D-5L instrument was less reproducible, the SF-6D instrument 25 
appeared to be applicable, valid, and reliable measure in assessing the HRQOL of Chinese 26 
patients with symptomatic benign thyroid nodules. Impact of utility score selection on the 27 
effectiveness and cost-effectiveness of clinical interventions targeted to these patients needs 28 
further exploration. 29 
 30 
Clinical trial number and registry: NCT02398721, ClinicalTrials.gov 31 
 32 
Key points 33 
• The SF-6D instrument appeared to be applicable, valid, and reliable measure in 34 
assessing the HRQOL of Chinese patients with symptomatic benign thyroid nodules. 35 
• The adoption of SF-6D utility score for health economic evaluation of clinical 36 
management on patients with symptomatic benign thyroid nodule was supported. 37 
  38 
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Manuscript Text 1 
 2 
INTRODUCTION 3 
 4 
Thyroid nodules are common and can be discovered by clinical palpation in 5% of normal 5 
individuals and by high-resolution ultrasonography (USG) in 60% of the general 6 
population[1, 2]. Although most nodules are benign and do not grow, some nodules do 7 
become large and symptomatic [1, 2]. Some patients may experience pain in the neck, jaw or 8 
ear and cosmetic unsightliness that adversely impacts appearance and social functioning. If 9 
left untreated, some patients may even experience difficulty with breathing and swallowing 10 
and even hoarseness of voice leading to impaired physical and mental health-related quality-11 
of-life (HRQOL). 12 
 13 
Patients’ HRQOL are not only affected by thyroid nodules themselves, but also by the 14 
subsequent treatments. There are essentially three therapeutic options for symptomatic benign 15 
thyroid nodules[3]. First is close surveillance with lifetime regular follow-ups. Although it is 16 
the least costly option, more costly treatments may follow if the disease progresses. Second is 17 
surgical resection or surgery. This is a “one-off” treatment and is associated with a high initial 18 
cost and patients may still need regular visits to check on their thyroid function afterwards. 19 
Third is non-surgical minimal invasive option which includes any form thermal ablative 20 
therapies or ethanol injection. This third option is usually a “one-off” treatment in most 21 
instances but it has the highest initial cost of the three options and regular visits are necessary. 22 
Recent longitudinal study on 40 patients with symptomatic nodule [4] reported that the 23 
thermal ablation after a two-year period was associated with physical and mental aspects of 24 
HRQOL improvements, possibly due to the reduction in compressive and cosmetic 25 
symptoms[5]. Based on a recent study[6], the non-surgical, minimally invasive option may 26 
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lead to greater improvement in HRQOL as compared to surgery but is unlikely to be cost-1 
effective over time at its current price. Besides treatment issues, patients enrolled to 2 
conservative management or close monitoring strategy may add uncertainty, anxiety and 3 
worries about the development of thyroid cancer. Often, the cost-effectiveness analysis of 4 
health interventions requires the input of health utility score, a composite preference-weight 5 
of HRQOL theoretically ranging from zero for death to one for full health. Although there is 6 
no general recommendation for a reference case and preferable health utility measure for 7 
economic evaluations in Hong Kong, a valid and reliable utility instrument is desirable to 8 
influence decision-making and cost-effectiveness analysis of treatment options for benign 9 
thyroid nodules.  10 
 11 
Therefore, measurement of HRQOL and utility scores are important in the subjective 12 
outcome and health economic evaluation of management for patients with symptomatic 13 
thyroid nodules. Indeed, to our knowledge, there are currently no disease-specific HRQOL 14 
instruments specifically designed for symptomatic benign nodular goitre, suggesting the use 15 
of existing generic HRQOL and utility score instruments might be acceptable. Although one 16 
previous study[6] estimated utility scores of patients with thyroid nodules through EuroQoL 17 
5-dimension (EQ-5D) instrument, the psychometric properties of the commonly used utility 18 
instruments, EQ-5D and Short-form 6-dimension (SF-6D) and their pairwise comparisons in 19 
patients with symptomatic benign thyroid nodules were not determined. Therefore, the 20 
present study aimed to assess the acceptability, validity, and reliability of the EQ-5D and SF-21 
6D instruments in patients with symptomatic benign thyroid nodules by doing a head-to-head 22 
comparison on psychometric properties among instruments.   23 
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METHODS AND PATIENTS 1 
Study design and Patients 2 
This was an interim analysis of data collected from an ongoing prospective trial (already 3 
approved by the local institutional review board and registered with www.clinicalTrials.gov 4 
(NCT02398721). Over a 9-month period, consecutive patients presenting for the first-time 5 
with a thyroid swelling were evaluated. To be eligible, first, the thyroid swelling had to be 6 
benign (i.e. Bethesda class II on fine needle aspiration cytology (FNAC) within 3 months of 7 
recruitment and a low or very-low suspicion sonographic pattern on USG). Second, the 8 
swelling (which could either be a solitary nodule or a dominant nodule in a multinodular 9 
gland) had to be causing obstructive or pressure symptoms. A swelling simply causing non-10 
specific neck complaints or cosmetic concern was not included. Third, the index nodule had 11 
to have all three orthogonal dimensions ≥10mm on USG. Also, patients with severe existing 12 
medical co-morbidities or terminal malignancy were not eligible. Patients with previous 13 
history of thyroid surgery, indeterminate, suspicious of malignancy or malignant FNAC (i.e. 14 
Bethesda class III or above) were excluded from current analysis.  15 
After informed consent, eligible patients were interviewed and were asked to fill in a 16 
structured HRQOL questionnaire consisting of the traditional Chinese (Hong Kong) version 17 
of SF-12 Health Survey version 2, SF-6D, EQ-5D 5-level (EQ-5D-5L), and questions on 18 
socio-demographics. As for consistency in administration modes, all patients were 19 
interviewer-administered because elderly patients with low literacy level were incompetent to 20 
self-complete questionnaires. The SF-12v2, SF-6D and EQ-5D-5L questionnaires were 21 
interviewer-administered at baseline, whereas three mentioned questionnaires and global 22 
rating of change scale were interview-administered at 2-week after baseline to assess test-23 
retest reliability.  24 
 25 
Study Instruments 26 
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EuroQoL 5-dimension 5-level (EQ-5D-5L) 1 
The EQ-5D-5L is a generic preference-based measure developed by the EuroQol Group for 2 
measurement of health-related quality-of-life, providing descriptions of five dimensions of 3 
health status. The EQ-5D-5L has five domain scales (mobility, self-care, usual activities, pain 4 
and discomfort, and anxiety and depression) and five levels for each domain. Since the 5 
Chinese-specific EQ-5D-5L value set / tariff is currently not available, we applied a two-step 6 
indirect approach to estimate EQ-5D-5L scores applicable for Chinese population, as adopted 7 
in previous studies[7-9]. The first step was the application of an indirect interim mapping 8 
method[10]. The EQ-5D-5L health status was transformed to EQ-5D-3L health status 9 
according to the transition probability matrix. Finally, EQ-5D-3L health status were scored 10 
according to a recently developed Chinese-specific EQ-5D-3L value set[11], ranging from -11 
0.149 for the worst health status (‘33333’) to 1 for the full health (‘11111’). A higher score in 12 
EQ-5D-5L indicated better HRQOL. 13 
 14 
Short-form 12-item Health Survey (SF-12) 15 
The Chinese (Hong Kong) SF-12 Health Survey version 2 (SF-12v2) has been validated and 16 
normed on the general Chinese population in Hong Kong. It measures eight domains of 17 
HRQOL on physical functioning (PF), role physical (RP), bodily pain (BP), general health 18 
(GH), vitality (VT), social functioning (SF), role emotional (RE) and mental health (MH) on 19 
a scale with theoretical range from 0 to 100. A higher score indicates better HRQOL. The 20 
eight domain scores were aggregated based on population-specific weights to calculate two 21 
summary scores, the physical (PCS) and mental component summary (MCS) scores.  22 
 23 
Short-form 6-dimension (SF-6D) 24 
In this study, the SF-6D utility score was directly converted from raw responses from SF-6D 25 
instrument. Specifically, estimation of SF-6D utility score is possible with the available item 26 
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responses of either SF-6D or SF-12v2[12] instrument. Previous research show that SF-6D 1 
utility score measured by SF-6D instrument was more sensitive and preferable than that 2 
derived from SF-12v2 instrument[13]. The Hong Kong SF-6D value set[14, 15] was derived 3 
by standard gamble valuation method[12]. The theoretical range of SF-6D utility score 4 
ranged from 1 for full health to 0.315 for the worse possible health state according to Chinese 5 
Hong Kong population-specific scoring algorithm [14, 15]. The SF-6D utility score serves as 6 
preference weighting input to quality-adjusted life-year outcomes in economic evaluation. 7 
 8 
Global Rating of Change Scale 9 
The global rating of change scale is a single item “Compared to the first visit, how would you 10 
rate your overall health now?” with 7-point Likert scale rating from ‘extremely worse’ (rating 11 
of -3) to ‘extremely better’ (rating of +3) health condition compared to previous assessment at 12 
baseline. It has widely used as an external criterion of change in heath condition[16, 17]. 13 
Patients self-rated ‘0’ as indication of ‘stable’ in health condition change were selected for 14 
test-retest reliability assessment. 15 
 16 
Statistical Analysis 17 
Descriptive statistics including mean, standard deviation (SD) and percentage of floor and 18 
ceiling of each subscale and each summary scale were calculated.  19 
 20 
The acceptability of instruments[18] was assessed using the proportion of missing values, and 21 
proportion of patients giving highest possible and lowest possible responses, denoted as 22 
ceiling effect and floor effect. At least 15% of subjects achieved the lowest or highest 23 
possible score was considered as the presence of floor or ceiling effect, respectively. Based 24 
on patients with stable in health condition over a 2-week duration, 2-week test-retest 25 
reliability was assessed by intra-class correlation (ICC) coefficient using a value ≥ 0.7 to 26 
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indicate adequate reproducibility. A weighted Kappa[19] of <0.2 was interpreted as poor 1 
agreement of individual domain responses between baseline and at 2-week assessments, 0.21-2 
0.4 as fair, 0.41-0.6 as moderate, 0.61-0.8 as good and >0.8 as very good. 3 
 4 
The construct validity[20] of the SF-6D and EQ-5D-5L utility score was assessed using 5 
correlation test against the SF-12v2 subscale scores holding similar constructs. Concerning 6 
the possible violation of normality assumption for HRQOL and health utility scores, 7 
Spearman’s rank correlation test was used. We hypothesized that the utility scores were 8 
moderately correlated with SF-12v2 summary scores, since those scores were composite 9 
scores of different important HRQOL domain scores. Data analyses were conducted using 10 
SPSS Windows 23.0 (IBM SPSS Inc., Chicago, IL, USA). P-value < 0.05 was statistically 11 
significant. 12 
 13 
  14 
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Results 1 
Baseline patient characteristics 2 
A total of 314 patients were enrolled and of these, 20 patients (6.5%) with previous history of 3 
thyroid surgery were excluded. Therefore, a total of 294 patients was included for analysis. 4 
Table 1 shows the characteristics of patients included in this study. The male:female ratio was 5 
1:6.4. The mean (± SD) age at presentation was 56.59 ± 11.67 years. The mean body mass 6 
index was 23.33 ± 3.29kg/m2. All of them were euthyroid on presentation. The mean serum 7 
TSH level was 1.33 ± 0.99mIU/L (normal: 0.05 – 4.2mIU/L). The majority (n=225, 71.7%) 8 
had multiple benign-looking nodules in their gland (i.e. multinodular goitre). The mean size 9 
of the dominant (largest) nodule was 2.4 ± 2.3cm (range: 1.6 – 3.8). 10 
 11 
Figure 1 plots the response distributions related to all dimensions of both the EQ-5D-5L and 12 
SF-6D instruments. Table 2 entails the descriptive statistics of health utility scores and 13 
detailed response distributions of EQ-5D-5L and SF-6D domains. The highest proportion of 14 
‘no problems’ response referred to social functioning domain in SF-6D and self-care domain 15 
in EQ-5D-5L. The mean EQ-5D-5L and SF-6D utility scores were 0.901 ± 0.113 and 0.773 ± 16 
0.139, respectively, where distribution of EQ-5D-5L was heavily left-skewed. Ceiling effect 17 
was observed for EQ-5D-5L. No significant (>15%) floor and ceiling effects were observed 18 
for SF-6D utility score. Table 3 depicts the two-week test-retest reliability among HRQOL 19 
and utility instruments. For two-week test-retest assessment, 130 patients completed the full 20 
set of HRQOL questionnaires. The mean follow-up duration was 17.1 days, with range from 21 
9 days to 51 days. Based on an external criterion indicating the change in health status 22 
compared to baseline assessment, 104 patients perceived stable in health condition over the 2-23 
week duration, where the retest time frame is commonly adopted for test-retest reliability[21]. 24 
The SF-6D utility scores showed good test-retest reliability (0.794; range: 0.696-0.860) but 25 
ICC of EQ-5D-5L score was less than 0.7.  26 
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Weighted kappa, indicating agreement between two assessments, was interpreted as fair-1 
moderate (0.223-0.445) for 6 dimensions of SF-6D, and poor-moderate (0.149-0.344) for 5 2 
dimensions of EQ-5D-5L. Better reliability was observed in SF-6D utility score than in EQ-3 
5D utility score. 4 
 5 
The SF-6D utility score had a moderate-strong Spearman rank correlation with SF-12v2 6 
domain and summary scores (0.461-0.630) that conceptually measures the similar construct 7 
providing evidence for adequate construct validity (Table 4). Only fair-to-moderate Spearman 8 
rank correlations between EQ-5D-5L score (0.310-0.552), and SF-12v2 domain scores were 9 
observed. Particularly Spearman correlations between EQ-5D-5L score and SF-12v2 10 
summary scores were fair-to-moderate (0.257-0.457).  11 
 12 
Discussion 13 
 14 
This psychometric validation study is the first report to evaluate acceptability, reliability, and 15 
validity of HRQOL and utility instruments in patients with symptomatic benign thyroid 16 
nodules. In evaluating acceptability, about half of patients self-reported the EQ-5D-5L health 17 
profile of ‘11111’, suggesting an observed ceiling effect for the EQ-5D-5L score. As such, 18 
EQ-5D-5L score may reflect the better health status condition of benign thyroid nodules and 19 
the lacking in room for improvement in health utility score due to clinical interventions. 20 
There was no observed floor and ceiling effects for the SF-6D score, demonstrating 21 
substantial acceptability of two instruments. The reliability of instruments are essential 22 
psychometric property of the HRQOL and utility assessment. It refers to the ability to 23 
reproduce consistent responses within a short period of time. The test-retest reliability of SF-24 
6D score was satisfactory, whereas EQ-5D-5L score had an inadequate reproducibility. The 25 
response test-retest reliability measured by weighted kappa was fair to moderate for SF-6D 26 
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dimensions but poor to moderate for EQ-5D-5L dimensions, in line with test-retest reliability 1 
of their utility scores. The reliability of SF-6D instrument was superior to that of EQ-5D-5L 2 
instrument for symptomatic benign thyroid nodules. To ascertain the construct validity of 3 
HRQOL and utility instrument, the generic SF-12v2 instrument was used as an anchor 4 
assessing whether dimension of SF-12v2 holds good correlation with dimensions in other 5 
instruments holding similar construct. Correlation between SF-12v2 dimension scores and 6 
utility scores reflected the significant strength of SF-6D over EQ-5D-5L. All subscale and 7 
summary scores of SF-12v2 were more correlated with SF-6D score than EQ-5D-5L score, in 8 
part due to the fact that items in SF-6D were extracted from SF-12 instrument. Moreover, SF-9 
6D score had moderate correlation to the physical (r=0.630) and mental (r=0.461) composite 10 
summary scores of SF-12v2 but weak correlation (r=0.257) between the EQ-5D-5L score and 11 
mental composite summary score of SF-12v2 was observed.  12 
 13 
One possible explanation for the differences in psychometric properties between SF-6D and 14 
EQ-5D-5L utility scores was in part due to the differential scoring algorithms available for 15 
the use in Hong Kong general and patient populations. Performance of acceptability and 16 
psychometric properties may be influenced by the scoring algorithms used for conversion. 17 
Unlike direct approach for calculation of SF-6D score, EQ-5D-5L utility score was derived 18 
via two-step indirect approach, interim mapping algorithm plus EQ-5D-5L value set derived 19 
by mainland China, which neither of them was not established based on Hong Kong Chinese 20 
population. Moderate correlation (r=0.556) between two utility scores reflected the reality 21 
that concepts in one utility score were not perfectly captured by another utility score, and thus 22 
echoed importance of utility instrument selection. Impact of utility score selection, referring 23 
to SF-6D score against EQ-5D-5L score, on quality-adjusted life-years, incremental cost-24 
effectiveness ratio and decision making of clinical interventions for thyroid nodule needs 25 
further exploration.  26 
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 1 
Limitations  2 
Notably, four instruments used in current study may not be the best available HRQOL and 3 
utility instruments designed for benign thyroid nodules. A recent systematic review[22] 4 
appraising quality of 14 standardized instruments recommended the use of ThyPRO 5 
instrument, initially developed by Danish research group, for HRQOL assessment in patients 6 
with benign thyroid diseases. The cross-cultural validity of ThyPRO have been assessed at 7 
multiple clinical sites at multiple countries[23]. However, the Chinese version, irrespective of 8 
simplified or traditional version, has not been validated and was available at the time of 9 
study. Future works on psychometric properties of ThyPRO instrument or other existing 10 
HRQOL instruments specific to symptomatic thyroid nodules are warranted to enable the 11 
subjective evaluation of clinical interventions over time as well as integration of HRQOL 12 
measurement into routine care of thyroid nodules. Secondly, unlike psychometric testing on 13 
instruments used for moderate and severe disease, HRQOL scores in benign thyroid nodule 14 
were not hypothesized to have significant correlations with any clinical characteristics such 15 
as size of nodule, number of nodules and treatment modalities. Therefore, no analysis was 16 
conducted to assess correlations between HRQOL and clinical characteristics. Thirdly, the 17 
SF-12v2 scores were in principle more correlated with SF-6D scores than other scores, given 18 
the fact that SF-6D is the abbreviated form of SF-12v2. There was a possibility of favoring 19 
SF-6D in evaluation of construct validity. In current study, The SF-6D score was not 20 
calculated from seven items responses from SF-12v2 instrument, i.e. SF-12 derived SF-6D 21 
score. Both the SF-6D and SF-12v2 instruments were separately administered to each patient, 22 
gathering different set of responses from two instruments. The SF-12 was assumed to be 23 
‘gold standard’ of HRQOL measurement testing against other HRQOL and utility scores. 24 
Nevertheless, this is presumably the best ‘gold standard’ among four instruments because this 25 
generic instrument has been validated in Hong Kong general population[24]. Since 26 
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instruments were not administered in a randomized order, there was also the possibility of 1 
context effect (or ‘order effect’) on HRQOL and utility measurement. Fourth, study was the 2 
secondary analyses of data collected within a RCT design. Since the RCT was not designed 3 
for purpose of psychometric evaluation, this paper lacks important information for a 4 
comprehensive acceptability investigation such as time for instrument completion, and 5 
patients’ perceived views and feedback on each instrument. Finally, the patients were 6 
sampled from endocrinology surgical outpatient clinic of one hospital in Hong Kong and so 7 
our findings might be less generalizable in non-Chinese populations. 8 
 9 
Conclusions 10 
 11 
The SF-6D instrument demonstrated satisfactory acceptability and psychometric properties in 12 
patients with symptomatic benign thyroid nodule, whilst the EQ-5D-5L instrument was less 13 
reproducible than SF-6D instrument at the test-retest assessment. These findings supported 14 
the use of the SF-6D instrument to evaluate the HRQOL in routine care as well as the 15 
adoption of its utility score in the health economic evaluation of patients with symptomatic 16 
benign thyroid nodule.  17 
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Figure Legend 2 
Figure 1. Response distribution of domains in SF-6D instrument (upper) and EQ-5D-5L 3 
instrument (lower). 4 
Tables  
 
Table 1. Baseline Characteristics of Patients with symptomatic thyroid nodules   
  
  
     
    
Total 
(N=294)       
Total (N=294) 
Characteristics N %   Characteristics N % 
Gender       The largest nodule     
 Male 40 13.61   Length (cm, Mean±SD) 1.52 0.37 
 Female 254 86.39   Width (cm, Mean±SD) 1.26 0.42 
Age (years, Mean±SD) 56.59 11.67   Height (cm, Mean±SD) 1.21 0.42 
Education     Volume (mL, Mean±SD)  1.47 1.17 
 No formal schooling 10 3.42   Position   
 Primary 54 18.49   Upper 25 9.26 
 Secondary 149 51.03   Middle 107 39.63 
 Tertiary or above 79 27.05   Lower 138 51.11 
Marital Status     Side   
 Married 211 72.01   Right 145 50.88 
 Single 36 12.29   Left 123 43.16 
 Widow(er) 24 8.19   Isthnmus 17 5.96 
 Separated or divorced 22 7.51  Number of nodules   
Currently Working     1 37 13.03 
 Yes 180 61.43   2 41 14.44 
 No 113 38.57   3 47 16.55 
 Unknown 
  
  4 54 19.01 
Monthly income     5 29 10.21 
 ≤HKD20,000 139 47.44   ≥6-<10 28 9.86 
 >HKD20,000 154 52.56   ≥10 48 16.90 
BMI (kg/m2, Mean±SD) 23.33 3.29  Treatment for thyroid disease   
serum TSH (mIU/L, Mean±SD) 1.33 0.99   RAI 3 1.02 
FT4 levels (Mean±SD) 18.09 10.43   Radiation 7 2.39 
     Operation 38 12.93 
            Thyroid-related medication 3 1.02 
Note:        
SD=standard deviation; BMI=body mass index; RAI=radioactive ablation iodine; TSH=thyroid-
stimulating hormone; FT4=free thyroxine; FNAC=fine-needle aspiration cytology  
  
Table 2. Descriptive statistics of health utility scores and response distributions related to all dimensions 
of EQ-5D-5L and SF-6D instruments at baseline 
       
Utility score Mean 
Standard 
deviation 
Observed 
Range 
Theoretical 
Range Floor (%) Ceiling (%) 
SF-6D score 0.773 0.139 0.41-1.00 0.32-1.00 0.0 1.3 
EQ-5D-5L score 0.901 0.113 0.51-1.00 -0.15-1.00 0.0 47.1 
 Response Distribution 
SF-6D Dimension (%) 1 2 3 4 5 6 
Physical functioning 24.5 32.7 28.6 12.2 1.7 0.3 
Role functioning 65.0 12.9 7.1 15.0   
Social functioning 72.8 17.0 6.8 2.7 0.7  
Pain 29.6 24.5 22.1 13.9 6.8 3.1 
Mental health 24.5 48.0 21.1 5.1 1.4  
Vitality 14.6 45.2 27.9 9.9 2.4  
EQ-5D-5L Dimension (%) 
1 (No 
problems) 
2 (Slight 
problems) 
3 (Moderate 
problems) 
4 (Severe 
problems) 
5 (Unable 
to)   
Mobility 87.4 9.5 3.1 0.0 0.0  
Self-care 97.6 2.0 0.0 0.0 0.3  
Usual activities 91.5 6.8 1.4 0.3 0.0  
Pain/discomfort 50.3 34.7 13.9 0.3 0.7  
Depression/anxiety 72.8 19.0 7.5 0.7 0.0   
       
 
 
  
Table 3. Two-week test-retest reliability of health utility scores 
    
  
Intra-class correlation 
(n=104) 
Utility score Estimate 95% CI 
SF-6D score 0.794 0.696 0.860 
EQ-5D-5L score 0.575 0.374 0.712 
  Weighted Kappa 
  Estimate 95% CI 
SF-6D    
Physical Functioning 0.278 0.159 0.396 
Role Limitation 0.342 0.215 0.469 
Social Functioning 0.340 0.178 0.501 
Pain 0.223 0.112 0.334 
Mental Health 0.445 0.319 0.570 
Vitality 0.404 0.289 0.519 
EQ-5D-5L    
Mobility 0.149 -0.007 0.306 
Self-care 0.241 0.098 0.384 
Usual activities 0.160 -0.033 0.352 
Pain/discomfort 0.344 0.193 0.495 
Depression/anxiety 0.231 0.072 0.390 
Note: CI = confidence interval    
    
 
  
Table 4. Spearman Correlation Coefficients between SF-12v2 subscale and summary scores and the 
health utility scores 
           
  SF-12v2 Subscale and Summary Scores 
Utility score PF RP BP GH VT SF RE MH PCS MCS 
SF-6D score 0.581 0.589 0.610 0.495 0.537 0.610 0.501 0.517 0.630 0.461 
EQ-5D-5L score 0.372 0.381 0.552 0.321 0.390 0.360 0.310 0.332 0.457 0.257 
Note:           
PF=physical functioning; RP=role physical; BP=bodily pain; GH=general health; VT=vitality; SF=social 
functioning; RE=role emotional; MH=mental health; PCS=Physical Composite Summary; MCS=Mental 
Composite Summary;  
 
 

